Core Points - Celularity Inc. has terminated its Chief Financial Officer, David Beers, effective immediately, without cause, and this decision is not related to the company's financial performance or reporting practices [1] - Joseph DosSantos, the current Senior Vice President of Finance, has been appointed as the interim CFO while the company searches for a new CFO [2] - The company has retained CFO Squad, a financial and business advisory firm, to provide outsourced accounting and consulting services during this transition period, focusing on SEC and financial reporting support [3] Company Overview - Celularity Inc. is a regenerative and cellular medicine company that develops and commercializes advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, utilizing the postpartum placenta [4]

Core Points - Celularity Inc. has been notified by Nasdaq for not timely filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025, resulting in non-compliance with Listing Rule 5250 (c)(1) [1] - The notice from Nasdaq does not have an immediate effect on the listing or trading of the Company's shares, and the Company has 60 calendar days to submit a compliance plan [2] - The Company is actively working to complete its Form 10-Q and anticipates maintaining compliance with SEC reporting obligations [3] Company Overview - Celularity Inc. is a regenerative and cellular medicine company focused on developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, utilizing the postpartum placenta [4]